Dyslipidemia

Type: Keyphrase

Name: Dyslipidemia

First reported Jun 17 2013 - Updated Jun 18 2013 - 2 reports

Lilly Study: Livalo Helps HIV Patients

New Data Showed Livalo (Pitavastatin) 4 Mg Had Neutral Effects on Fasting Serum Glucose and Hba1c Levels in HIV-Infected Adults With Dyslipidemia Study results presented at ENDO 2013 Annual Meeting SAN FRANCISCO, June 17, 2 ... [Published Drugs.com - Jun 18 2013]

Entities: HIV/AIDS, Patient, Pitavastatin, Dyslipidemia, Glycated Hemoglobin

First reported Jun 17 2013 - Updated Jun 17 2013 - 1 reports

Global Dyslipidemia Pipeline Capsule - 2013

Research and Markets (http://www.researchandmarkets.com/research/rkxgmt/global) has announced the addition of the " " report to their offering. Fore Pharma's latest report Global Dyslipidemia Pipeline Capsule - 2013' provides up-to-date information on ... [Published Individual.com - Jun 17 2013]

Entities: Dyslipidemia, Pipeline, Clinical trials, Molecule

First reported Jun 15 2013 - Updated Jun 15 2013 - 1 reports

Zydus Pioneers a Breakthrough With LIPAGLYN, India's First NCE to Reach the Market

SOURCE Cadila HealthcareMUMBAI, IndiaLipaglyn™ is the first Glitazar to be approved in the world and the first NCE discovered and developed indigenously by an Indian Pharma Company.The Zydus Group announced a breakthrough in its research efforts with ... [Published KLFY - Jun 15 2013]

Entities: Cholesterol, Cadila Healthcare Limited, India

First reported Jun 12 2013 - Updated Jun 13 2013 - 1 reports

Netherlands' Dezima Pharma Appoints New CEO

Dezima Pharma BV, a Dutch company developing therapies for dyslipidemia, has appointed Rob de Ree as its new chief executive months after raising Series A financing for a new drug study to begin this year.Dyslipidemia is an abnormal amount of cholesterol ... [Published Dow Jones Financial Information Services - Jun 12 2013]

Entities: Appointed, Netherlands, Dyslipidemia, Cholesterol

First reported Jun 07 2013 - Updated Jun 07 2013 - 1 reports

IndiaNivesh Securities recommends Cadila Healthcare; target price Rs 913

Cadila announced launch of its first NCE (New Chemical Entity) into domestic markets, which is likely to be marketed in India under the brand name of LIPAGLYN, which is the first Glitazar category drug to be approved in the world and is the first NCE ... [Published Smart Investor - Jun 07 2013]

Entities: Cadila Healthcare Limited, Drug Controller General of India, Dyslipidemia, non-insulin-dependent diabetes mellitus, Statins

First reported Jun 06 2013 - Updated Jun 06 2013 - 1 reports

Pharmaceuticals Newsletter - May 31 to June 06, 2013

Zydus Cadila has announced a breakthrough in the anti-diabetic drug Lipaglyn. Lipaglyn - The worldâs first drug for treating Diabetic Dyslipidemia combines lipid and glucose lowering effects in one single molecule. ... [Published India Infoline - Jun 06 2013]

Entities: Dyslipidemia, Cadila Healthcare Limited, Glucose, Molecule

First reported Jun 05 2013 - Updated Jun 06 2013 - 5 reports

Zydus Pioneers a Breakthrough With LIPAGLYN Indias First NCE to Reach the Market

/CNW/ - Lipaglyn(TM) is the first Glitazar to be approved in the world and the first NCE discovered and developed indigenously by an Indian Pharma Company. The Zydus Group announced a breakthrough in its research efforts with Lipaglyn(TM) (Saroglitazar), ... [Published Big News Network - Jun 05 2013]

Entities: Market, India, Hypertriglyceridemia, Drugs, Dyslipidemia

First reported Jun 04 2013 - Updated Jun 04 2013 - 1 reports

Independent Association Between Nocturnal Intermittent Hypoxemia and Metabolic Dyslipidemia Metabolic Dyslipidemia in Obstructive Sleep Apnea

Background: There is growing evidence from animal models that intermittent hypoxemia (IH) may induce dyslipidemia. Altered lipid metabolism may contribute to the increased cardiovascular risk observed in obstructive sleep apnea (OSA). In this multisite, ... [Published CHEST - Jun 04 2013]

Entities: Obstructive Sleep Apnea, Dyslipidemia, Cholesterol, Lipoprotein

First reported May 28 2013 - Updated May 29 2013 - 1 reports

AstraZeneca to Acquire Omthera Pharmaceuticals Including NDA-Ready Novel Dyslipidemia Treatment to Complement Cardiovascular Portfolio

/PRNewswire/ --$ AstraZeneca today announced that it has entered into a definitive agreement to acquire Omthera Pharmaceuticals, a specialty pharmaceutical company based in Princeton, New Jersey , focused on the development and commercialization of new ... [Published Barchart - May 28 2013]

Entities: Omthera Pharmaceuticals Inc, Epanova, AstraZeneca PLC, Triglycerides

First reported May 28 2013 - Updated May 28 2013 - 1 reports

AstraZeneca to Acquire Omthera Pharmaceuticals Including NDA-Ready Novel Dyslipidemia Treatment to Complement Cardiovascular Portfolio

OMTHERA PHARMACEUTICALS INC Symbol U : OMTH Recent Sedar Documents AstraZeneca to Acquire Omthera Pharmaceuticals Including NDA-Ready Novel Dyslipidemia Treatment to Complement Cardiovascular Portfolio ... [Published Stockwatch - May 28 2013]

Entities: Omthera Pharmaceuticals Inc, Dyslipidemia, AstraZeneca PLC

First reported May 23 2013 - Updated May 23 2013 - 1 reports

Monmouth University awards first - and only - doctorate

Barbara Scarano, 67, of the Shark River Hills section of Neptune, attended Bellevue Hospital School of Nursing for undergraduate studies and in 2001 earned her Masters of Science in Nursing at Monmouth University with an accompanying certification as ... [Published Asbury Park Press - May 23 2013]

Entities: Monmouth University, Rugby School, Dyslipidemia

First reported May 01 2013 - Updated May 01 2013 - 1 reports

17th Annual CME Conference for Primary Care Physicians on...

. is pleased to offer the Continuing Medical Education (CME) In collaboration with the Carolinas, Georgia, Florida Chapter of the American Society of Hypertension, . is pleased to offer the This three-day intensive conference will be held on June 28-30, ... [Published PRWeb - May 01 2013]

Entities: Hypertension, American Society of Hypertension, Dyslipidemia, Diabetes

Quotes

...that patients living with HIV infection have increased cardiovascular disease risk factors, including dyslipidemia and glucose abnormalities.2$ $ "We are pleased with the results of this safety analysis that showed neutrality for the maximum dose of pitavastatin 4 mg on parameters of glucose metabolism, which are consistent with our previous findings in non-HIV-infected adult populations with dyslipidemia" said Dr. Craig Sponseller, Vice President of Medical Affairs at Kowa Pharmaceuticals America, Inc

New Data Showed LIVALO® (pitavastatin) 4 mg had Neutral Effects on Fasting Serum Glucose and HbA1 ... [Published Yahoo! Finance - Jun 17 2013]

"Lipaglyn™ provides patients suffering from diabetic dyslipidemia the option of a once-daily oral therapy that has a beneficial effect on both lipid parameters as well as glycemic control" said Mr. Pankaj Patel

Zydus Pioneers a Breakthrough With LIPAGLYN, India's First NCE to Reach the Market [Published KLFY - Jun 15 2013]

Dezima Pharma ( "Dezima'), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today that it has appointed Rob de Ree as its new Chief Executive Officer."

Dezima Pharma Appoints Seasoned New CEO [Published FinanzNachrichten.de - Jun 12 2013]

"We expect Lipaglyn to be a blockbuster drug reaching $1 billion in annual sales globally. While the pricing and distribution aspects are being currently worked out, we are looking to introduce it in India by third quarter of this fiscal" said Patel

Cadila launches India's first new drug [DNA : Daily News & Analysis (India)] [Published Pharmacy Choice - Jun 06 2013]

More Content

sort by: Date \| Relevance
Amarin Informed by FDA of October 16th Advisory... [Published GlobeNewswire: Acquisitions News - 2 hours ago]
Lilly Study: Livalo Helps HIV Patients [Published Drugs.com - Jun 18 2013]
New Data Showed LIVALO® (pitavastatin) 4 mg had... [Published Yahoo! Finance - Jun 17 2013]
New Data Showed LIVALO® (pitavastatin) 4 mg had... [Published PR Newswire: Health - Jun 17 2013]
Research and Markets: Global Dyslipidemia Pipel... [Published Business Wire Professional Services News - Jun 17 2013]
Global Dyslipidemia Pipeline Capsule - 2013 [Published Individual.com - Jun 17 2013]
Zydus Pioneers a Breakthrough With LIPAGLYN, In... [Published KLFY - Jun 15 2013]
New Market Report: EpiCast Report: Dermatophyti... [Published SBWire - Jun 14 2013]
Netherlands' Dezima Pharma Appoints New CEO [Published Dow Jones Financial Information Services - Jun 12 2013]
Dezima Pharma Appoints Seasoned New CEO [Published FinanzNachrichten.de - Jun 12 2013]
IndiaNivesh Securities recommends Cadila Health... [Published Smart Investor - Jun 07 2013]
Cadila launches India's first new drug [DNA : D... [Published Pharmacy Choice - Jun 06 2013]
Pharmaceuticals Newsletter - May 31 to June 06,... [Published India Infoline - Jun 06 2013]
Research and Markets: Mixed Dyslipidemia - Pipe... [Published Business Wire Health News - Jun 05 2013]
Cegedim Strategic Data's Real-World Evidence Sh... [Published Individual.com - Jun 05 2013]
Zydus Pioneers a Breakthrough With LIPAGLYN Ind... [Published Big News Network - Jun 05 2013]
Cadila Healthcare in reverse gear [Published India Infoline - Jun 05 2013]
Zydus announces breakthrough in anti-diabetic d... [Published India Infoline - Jun 05 2013]
Zydus Pioneers a Breakthrough With LIPAGLYN, In... [Published PR Newswire - Jun 05 2013]
Zydus Pioneers a Breakthrough With LIPAGLYN, In... [Published Michigan Live - Jun 05 2013]
Zydus announces breakthrough in anit-diabetic d... [Published India Infoline - Jun 05 2013]
Independent Association Between Nocturnal Inter... [Published CHEST - Jun 04 2013]
Now Available: EpiCast Report: Pediatric Respir... [Published SBWire - Jun 03 2013]
Selective peroxisome proliferator-activated rec... [Published Cardiovascular Diabetology - May 31 2013]
AstraZeneca PLC : Acquires Omthera Pharmaceuticals [Published Investegate - May 28 2013]
AstraZeneca to Acquire Omthera Pharmaceuticals ... [Published Stockwatch - May 28 2013]
AstraZeneca to Acquire Omthera Pharmaceuticals ... [Published Barchart - May 28 2013]
AstraZeneca to Acquire Omthera Pharmaceuticals ... [Published PR Newswire: Financial Services - May 28 2013]
Global Dyslipidemia Pipeline Capsule - 2013 [Published Research and Markets - May 23 2013]
Monmouth University awards first - and only - d... [Published Asbury Park Press - May 23 2013]